• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国制药公司的特点、风险管理和 GMP 标准。

Characteristics, risk management and GMP standards of pharmaceutical companies in China.

机构信息

Anhui University of Finance and Economics, Bengbu, Anhui, China.

University of Waterloo, Waterloo, ON, Canada.

出版信息

Front Public Health. 2023 Mar 8;11:1103555. doi: 10.3389/fpubh.2023.1103555. eCollection 2023.

DOI:10.3389/fpubh.2023.1103555
PMID:36969675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10031010/
Abstract

The Good Manufacturing Practice (GMP) is one of the gold standards by which governments worldwide judge modern pharmaceutical companies' production processes and product-safety standards. However, in all the nations, it is difficult to obtain real data about GMP inspection results, so conducting the related research is impossible. Taking advantage of a rare chance to obtain the on-site GMP inspection results in China, we have been able to initiate an empirical analysis of how company characteristics and risk management affect the GMP inspection results of certain pharmaceutical companies. The 2SLS method regression was employed in this study. Our four main findings are as follows. First, compared with Chinese state-owned companies, foreign commercial and private enterprises are held to higher standards. Second, the GMP inspection results tend to be better for those enterprises whose main sources of capital are not dependent on bank loans. Third, enterprises with higher fixed assets tend to receive the better GMP inspection results. Fourth, the longer the quality authorized staff has worked in a company, the better the GMP inspection results expected of that enterprise. These findings offer insights into inspections and production improvements in China and other GMP-compliant countries.

摘要

良好生产规范(GMP)是世界各国政府评判现代制药公司生产流程和产品安全标准的黄金标准之一。然而,在所有国家,都很难获得关于 GMP 检查结果的真实数据,因此相关研究无法开展。我们利用一次难得的机会获取了中国的现场 GMP 检查结果,从而能够对公司特征和风险管理如何影响某些制药公司的 GMP 检查结果展开实证分析。本研究采用了两阶段最小二乘法(2SLS)回归。我们的四项主要发现如下。第一,与中国国有企业相比,外资商业企业和私营企业的标准更高。第二,那些主要资金来源不依赖银行贷款的企业,其 GMP 检查结果往往更好。第三,固定资产较高的企业往往会获得更好的 GMP 检查结果。第四,质量授权人员在公司工作的时间越长,企业预期的 GMP 检查结果就越好。这些发现为中国和其他符合 GMP 标准的国家的检查和生产改进提供了参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/10031010/c9d9d306775b/fpubh-11-1103555-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/10031010/2339d325de39/fpubh-11-1103555-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/10031010/c9d9d306775b/fpubh-11-1103555-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/10031010/2339d325de39/fpubh-11-1103555-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/10031010/c9d9d306775b/fpubh-11-1103555-g0002.jpg

相似文献

1
Characteristics, risk management and GMP standards of pharmaceutical companies in China.中国制药公司的特点、风险管理和 GMP 标准。
Front Public Health. 2023 Mar 8;11:1103555. doi: 10.3389/fpubh.2023.1103555. eCollection 2023.
2
Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.巴基斯坦当地制药行业实施和遵守国际公认质量标准的体制障碍和促进因素:一项定性研究。
Health Policy Plan. 2019 Jul 1;34(6):440-449. doi: 10.1093/heapol/czz054.
3
Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.制药生产质量投资的成本效益:一家尼日利亚制药商的世卫组织药品生产质量管理规范认证前后情况
BMC Health Serv Res. 2017 Sep 18;17(1):665. doi: 10.1186/s12913-017-2610-8.
4
Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.援助条件、国际药品生产质量管理规范标准与本土生产权:尼泊尔本土生产案例研究
Global Health. 2015 Jun 14;11:25. doi: 10.1186/s12992-015-0110-3.
5
[Pharmaceutical product quality control and good manufacturing practices].[药品质量控制与良好生产规范]
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2010(128):1-16.
6
An assessment of adherence to the WHO-delineated good manufacturing practice by the pharmaceutical companies in Kabul, Afghanistan.对阿富汗喀布尔制药公司遵守世界卫生组织规定的药品生产质量管理规范情况的评估。
Cost Eff Resour Alloc. 2022 Apr 2;20(1):17. doi: 10.1186/s12962-022-00348-1.
7
[Early achievements of the Danish pharmaceutical industry--8. Lundbeck].[丹麦制药行业的早期成就——8. 灵北公司]
Theriaca. 2016(43):9-61.
8
[An analysis of the pharmaceuticals market in Vietnam].[越南药品市场分析]
Sante. 2001 Jul-Sep;11(3):155-60.
9
The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.对比药品生产质量管理规范,生产高活性或致敏性药物的要求。
Acta Biomed. 2019 May 23;90(2):288-299. doi: 10.23750/abm.v90i2.8340.
10
Drugs quality supervision strategy of different distribution channels in pharmaceutical supply chain.药品供应链不同分销渠道的药品质量监管策略。
Front Public Health. 2022 Oct 11;10:954371. doi: 10.3389/fpubh.2022.954371. eCollection 2022.

引用本文的文献

1
Preventing Microorganism Contamination in Starting Active Materials for Synthesis from Global Regulatory Agencies: Overview for Public Health Implications.全球监管机构对合成起始活性材料中微生物污染的预防:对公共卫生影响的概述
Microorganisms. 2025 Jul 6;13(7):1595. doi: 10.3390/microorganisms13071595.
2
The impact of corporate governance on the total factor productivity of pharmaceutical enterprises: a study based on the fsQCA method.公司治理对医药企业全要素生产率的影响:基于 fsQCA 方法的研究。
Sci Rep. 2024 Feb 8;14(1):3285. doi: 10.1038/s41598-024-52751-8.

本文引用的文献

1
Pharmaceutical good manufacturing practice: Leuplin production in Japan identifies major international shortcomings.药品生产质量管理规范:日本来那度胺生产揭示重大国际缺陷。
Invest New Drugs. 2021 Aug;39(4):1167-1169. doi: 10.1007/s10637-021-01080-y. Epub 2021 Feb 9.
2
How migrants get integrated in urban China - The impact of health insurance.移民如何融入中国城市——医疗保险的影响。
Soc Sci Med. 2021 Mar;272:113700. doi: 10.1016/j.socscimed.2021.113700. Epub 2021 Jan 14.
3
Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
巴基斯坦当地制药行业实施和遵守国际公认质量标准的体制障碍和促进因素:一项定性研究。
Health Policy Plan. 2019 Jul 1;34(6):440-449. doi: 10.1093/heapol/czz054.
4
The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products.RIMES 声明:评估药品风险最小化计划研究质量的清单。
Drug Saf. 2018 Apr;41(4):389-401. doi: 10.1007/s40264-017-0619-x.
5
Measuring the efficiency of large pharmaceutical companies: an industry analysis.衡量大型制药公司的效率:行业分析。
Eur J Health Econ. 2017 Jun;18(5):587-608. doi: 10.1007/s10198-016-0812-3. Epub 2016 Jun 25.
6
Innovation in the pharmaceutical industry: New estimates of R&D costs.制药行业的创新:研发成本的新估计
J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12.
7
Improving pharmaceutical innovation by building a more comprehensive database on drug development and use.通过建立一个关于药物研发和使用的更全面的数据库来改善药物创新。
Health Aff (Millwood). 2015 Feb;34(2):319-27. doi: 10.1377/hlthaff.2014.1019.